Free Trial
NASDAQ:VYGR

Voyager Therapeutics Q2 2025 Earnings Report

Voyager Therapeutics logo
$3.36 -0.04 (-1.18%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$3.42 +0.06 (+1.79%)
As of 08/29/2025 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Voyager Therapeutics EPS Results

Actual EPS
-$0.57
Consensus EPS
-$0.48
Beat/Miss
Missed by -$0.09
One Year Ago EPS
N/A

Voyager Therapeutics Revenue Results

Actual Revenue
$5.20 million
Expected Revenue
$9.50 million
Beat/Miss
Missed by -$4.30 million
YoY Revenue Growth
N/A

Voyager Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 6, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Voyager Therapeutics' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Thursday, November 6, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Voyager Therapeutics Earnings Headlines

Voyager to Present at Upcoming Investor Conferences
What Steve Bannon revealed about Trump’s gold play
A Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your IRA could be at risk. Here’s how to prepare.tc pixel
Voyager Therapeutics (VYGR) Receives a Buy from Oppenheimer
See More Voyager Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Voyager Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Voyager Therapeutics and other key companies, straight to your email.

About Voyager Therapeutics

Voyager Therapeutics (NASDAQ:VYGR), a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

View Voyager Therapeutics Profile

More Earnings Resources from MarketBeat